STOK Stock Analysis: Buy, Sell, or Hold?
STOK - Stoke Therapeutics, Inc. Common Stock
$31.89
0.92 (2.97%)
▲
5d:
+6.3%
30d:
+7.48%
90d:
-4.52%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When STOK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: STOK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: STOK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: STOK is currently trading at $31.89, which is considered extended relative to its 30-day fair value range of $29.17 to $30.93.
Technical Outlook: Technically, STOK is in a strong uptrend. The price is approaching resistance at $32.36. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: STOK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.10 (+45.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, STOK is in a strong uptrend. The price is approaching resistance at $32.36. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: STOK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.10 (+45.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$29.17 -
$30.93
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.6% below Wall St target ($45.10)
Trading Range Analysis
30-Day Trading Range
$29.17 -
$30.93
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$28.12
Resistance Level
$32.36
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.98
Wall Street Target
$45.10
(+45.6%)
Revenue Growth (YoY)
-96.1%
Share & Embed Analysis
Last updated: June 23, 2026 1:14 PM ET
Data refreshes hourly during market hours. Next update: 2:14 PM
Data refreshes hourly during market hours. Next update: 2:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is STOK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Barry Ticho
SELL
1461 shares
2026-03-19
Thomas Leggett
SELL
2382 shares
2026-03-18
Jonathan Allan
SELL
4628 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 69 BUY |
Advanced STOK Option Strategies
Professional options setups generated by AI based on today's STOK price and gamma walls.
